User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

10594

Interactions with Platform & by Email *

INTERACTIONS

1271

Unique # Participated *

PARTICIPANTS

318

Responses Validated *

VALIDATIONS

34

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability And Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   What is Migraine?.....II-1
What Causes Migraine?.....II-1
1$175
   Migraine Classification.....II-2
Migraine with Aura.....II-2
Migraine without Aura.....II-2
Aura without Headache.....II-2
Abdominal Migraine.....II-2
1$175
   Facial Migraine.....II-3
Basilar Migraine.....II-3
Familial Hemiplegic Migraine.....II-3
Ophthalmoplegic/Ocular Migraine.....II-3
Retinal Migraine.....II-3
Menstrual Migraine.....II-3
Status Migraine.....II-3
1$175
   Migraine Attack Stages.....II-4
I – The Prodrome Stage.....II-4
II – The Aura Stage.....II-4
III – The Headache Stage.....II-4
IV – The Postdrome Stage.....II-4
1$175
   Historical Perspective.....II-5
Migraine Treatment.....II-5
Abortive Drugs.....II-5
Selective Serotonin Receptor (5- HTI) Agonists/ Triptans.....II-5
1$175
   Triptans Approved for the Treatment of Migraine.....II-6
Ergot Alkaloids.....II-6
1$175
   Ergot Alkaloids for the Treatment of Migraine.....II-7
Antiemetics.....II-7
Antiemetics for the Treatment of Migraine.....II-7
Analgesics.....II-7
1$175
   Analgesics for the Treatment of Migraine.....II-8
Prophylactic Drugs.....II-8
1$175
   Beta-Blockers.....II-9
Calcium Channel Blockers.....II-9
Anticonvulsants.....II-9
Tricyclic Antidepressants.....II-9
Non-steroidal Anti-inflammatory Drugs.....II-9
1$175
   Selective Serotonin Reuptake Inhibitors.....II-10
Serotonin Antagonists.....II-10
Anti-migraine Drugs: Side Effects.....II-10
Abortive Drugs: Side Effects.....II-10
1$175
   Prophylactic Drugs: Side Effects.....II-11
Anti-migraine Drugs: Interactions.....II-11
1$175
   Abortive Medications: Interactions.....II-12
Prophylactic Drugs: Interactions.....II-12
2$225
   Pipeline Drug Research.....II-14
Pipeline Drug Candidates in Phase III Clinical Trials.....II-14
Pipeline Drug Candidates in Phase II Clinical Trials.....II-14
Clinical Research / Drug Development Initiatives.....II-14
MAP Pharma Announces Positive Phase III Results for Levadex.....II-14
1$175
   Addex Initiates Phase IIb Trials for ADX 10059.....II-15
Asterand and BTG Announce Plans to Commence Phase IIa Trials.....II-15
Alexza Commences Phase IIb Trials of AZ-104.....II-15
Neuralieve Announces Trial Completion of New Migraine Treatment Device.....II-15
1$175
   NeurAxon Announces Encouraging Results of Phase 2 Trials.....II-16
Roxro Pharma Announces ROX-828 Results.....II-16
Merck Announces Encouraging Results of Phase III Study of Telcagepant.....II-16
ProEthic Pharmaceuticals Reports Encouraging Phase III Results.....II-16
1$175
   Recent Migraine Research.....II-17
Study Reveals Cocoa Consumption to Ease Migraine.....II-17
Study Reveals Women with Migraine to be At Lesser Risk of Breast Cancer.....II-17
Study Shows Risk of Migraine to be Less Among High Blood Pressure Patients.....II-17
1$175
   A. Market Analysis.....II-18
Current & Future Analysis.....II-18
Historic Analysis.....II-18
Migraine – Prevalence and Economic Burden.....II-18
Anti-Migraine Drugs Market At A Glance.....II-18
1$75
   Triptans – Leading the Anti-Migraine Treatment Race.....II-19
Generic Imitrex Make Foray.....II-19
Botox – An Emerging Option for Migraine Prophylaxis.....II-19
1$75
   Anti-migraine Drugs – Limitations Abound.....II-20
The Quest to Unravel the Mystery of Cause of Migraine Continues .....II-20
Strategic Corporate Developments.....II-20
Zogenix, Astellas Pharma Sign Agreement for Sumavel DosePro.....II-20
1$75
   Kowa Pharma to Divest Diclofenac Franchise.....II-21
Zogenix Wins FDA Approval for Sumavel DosePro.....II-21
Orchid Pharma Obtains FDA Approval for Sumatriptan Succinate Tablets.....II-21
Sandoz Unveils Sumatriptan and Calcitonin- Salmon Nasal Spray.....II-21
1$75
   Wockhardt to Introduce Divalproex ER.....II-22
Ranbaxy Receives FDA Approval for Imitrex Generic.....II-22
Kowa America Secures FDA Approval for Cambia.....II-22
Almirall Receives FDA Approval for Axert/ Almogran.....II-22
1$75
   Wockhardt Receives FDA Approval for Sumatriptan Injections.....II-23
Teva Pharmaceutical Secures Approval, Launches Imitrex Generic.....II-23
AstraZeneca Unveils Zomig Rapimeltt in 5 mg Dosage Strength.....II-23
Bedford Laboratories Launches Sumatriptan Succinate Injection.....II-23
Ipca Laboratories and Heritage Pharmaceuticals Announce Strategic Alliance.....II-23
1$75
   Dr. Reddy's Introduces Approved Imitrex® Generic.....II-24
US FDA Approves Divalproex Sodium Tablets.....II-24
GSK and Pozen Announce FDA Approval for Treximet.....II-24
Aurobindo Wins Provisionary Approval for Sumatriptan Succinate Tablets.....II-24
1$75
   Par Pharmaceuticals to Commence Shipment of Imitrex’s Generic Version.....II-25
Select Players.....II-25
Abbott Laboratories, Inc......II-25
Eisai, Inc......II-25
1$75
   Eli Lilly and Company.....II-26
Johnson & Johnson, Inc......II-26
1$75
   Kowa Pharmaceuticals America, Inc......II-27
MAP Pharmaceuticals, Inc......II-27
Merck & Co., Inc......II-27
1$75
   Pfizer, Inc......II-28
Pozen.....II-28
1$75
   Roxro Pharma, Inc......II-29
Winston Pharmaceuticals, Inc......II-29
Wyeth Consumer Healthcare.....II-29
1$75
   Zogenix, Inc......II-30
B. Market Analytics.....II-30
Table 1: US Recent Past, Current & Future Analysis for Anti-Migraine Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-30
1$200
   Table 2: US Historic Analysis for Anti-Migraine Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-311$200
   A. Market Analysis.....II-32
Current & Future Analysis.....II-32
Historic Analysis.....II-32
Strategic Corporate Developments.....II-32
Orexo Acquires PharmaKodex.....II-32
1$75
   Noxxon Pharma Collaborates with Eli Lilly.....II-33
Select Players.....II-33
AstraZeneca Plc (UK).....II-33
Bayer AG (Germany).....II-33
1$75
   Ethypharm S.A. (France).....II-34
GlaxoSmithKline Plc (UK).....II-34
Meda AB (Sweden).....II-34
1$75
   Novartis AG (Switzerland).....II-35
UCB S.A. (Belgium).....II-35
1$75
   B. Market Analytics.....II-36
Table 3: European Recent Past, Current & Future Analysis for Anti-Migraine Drugs by Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-36
1$200
   Table 4: European Historic Analysis for Anti- Migraine Drugs by Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figure in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-371$200
   Table 5: European 15-year Perspective for Anti-Migraine Drugs by Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-381$200
   A. Market Analysis.....II-39
Current & Future Analysis.....II-39
Historic Analysis.....II-39
B. Market Analytics.....II-39
Table 6: French Recent Past, Current & Future Analysis for Anti-Migraine Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-39
1$200
   Table 7: French Historic Analysis for Anti-Migraine Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-401$200
   A. Market Analysis.....II-41
Current & Future Analysis.....II-41
Historic Analysis.....II-41
B. Market Analytics.....II-41
Table 8: German Recent Past, Current & Future Analysis for Anti-Migraine Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-41
1$200
   Table 9: German Historic Analysis for Anti-Migraine Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-421$200
   A. Market Analysis.....II-43
Current & Future Analysis.....II-43
Historic Analysis.....II-43
B. Market Analytics.....II-43
Table 10: Italian Recent Past, Current & Future Analysis for Anti-Migraine Drugs -Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-43
1$200
   Table 11: Italian Historic Analysis for Anti-Migraine Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-441$200
   A. Market Analysis.....II-45
Current & Future Analysis.....II-45
Historic Analysis.....II-45
Migraine – Prevalence.....II-45
Migraine Treatment.....II-45
Abortive Drugs.....II-45
1$75
   List of Abortive Anti-Migraine Drugs Available in the UK.....II-46
Prophylactic Drugs.....II-46
List of Prophylactic Anti-Migraine Drugs Available in the UK.....II-46
1$75
   B. Market Analytics.....II-47
Table 12: UK Recent Past, Current & Future Analysis for Anti-Migraine Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-47
1$200
   Table 13: UK Historic Analysis for Anti-Migraine Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-481$200
   A. Market Analysis.....II-49
Current & Future Analysis.....II-49
Historic Analysis.....II-49
B. Market Analytics.....II-49
Table 14: Spanish Recent Past, Current & Future Analysis for Anti-Migraine Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-49
1$200
   Table 15: Spanish Historic Analysis for Anti-Migraine Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-501$200
   A. Market Analysis.....II-51
Current & Future Analysis.....II-51
Historic Analysis.....II-51
Ireland.....II-51
1$75
   B. Market Analytics.....II-52
Table 16: Rest of Europe Recent Past, Current & Future Analysis for Anti-Migraine Drugs -Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-52
1$200
   Table 17: Rest of Europe Historic Analysis for Anti-Migraine Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-531$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com